WHO says: We have full confidence in the Indian industry, Bharat Biotech is collecting data regularly

World Desk, Amar Ujala, Geneva

Published by: Gaurav Pandey
Updated to Thursday, 28 October 2021 10:28 PM IST

Summary

Regarding the delay in obtaining permission for the emergency use of the anti-corona vaccine covaccine, a World Health Organization official said, “We have full confidence in the Indian industry. A decision on Kovacsin could be made within the next week, the official said.

Kovacin vaccine
– Photo: Twitter

Listen to the news

A World Health Organization (WHO) official said on Thursday that “we have full confidence in the Indian industry for the manufacture of high quality vaccines.” Bharat Biotech is regularly and expeditiously submitting data to the Technical Committee on Permission (EUL) to list the covaxin vaccine for emergency use, the official said. He hopes the committee will send its final recommendation to the WHO within the next week.

Hyderabad-based Bharat Biotech has developed an anti-coronavirus vaccine called Kovacin. The company submitted an EOI to the WHO on April 19 for the EUL of this vaccine. The UN Health Organization’s technical advisory team met on Tuesday. The group has sought further clarification from Bharat Biotech to conduct a final risk-benefit assessment for placing Kovacsin on the emergency consumption list.

Dr Mariangela Simao, Assistant Director General (Access to Pharmaceuticals and Health Products) at the WHO, told a news conference in Geneva that India Biotech was collecting data regularly and rapidly. However, he submitted the final data on October 18. When China’s coronavirus vaccines were approved despite the absence of synoform and synovac data, she responded to the question of the delay in placing Kovacsin on the emergency use list.

When the technical advisory team met on October 26 to discuss the EUL for Kovacsin, Simao said he had sought further clarification from Bharat Biotech. The WHO works closely with Bharat Biotech and interacts daily with a team of technicians to provide the required data. So far, the WHO has allowed emergency use of Pfizer-Bioentech, Astrogeneneka, Johnson & Johnson, Modernna and Sinofarm.

Expansion

A World Health Organization (WHO) official said on Thursday that “we have full confidence in the Indian industry for the manufacture of high quality vaccines.” The official said that Bharat Biotech is regularly and expeditiously submitting data to the Technical Committee on Permission (EUL) to list the covaxin vaccine for emergency use. He hopes the committee will send its final recommendation to the WHO within the next week.

Hyderabad-based Bharat Biotech has developed an anti-coronavirus vaccine called Kovacin. The company submitted an EOI to the WHO on April 19 for the EUL of this vaccine. The UN Health Organization’s technical advisory team met on Tuesday. The group has sought further clarification from Bharat Biotech to conduct a final risk-benefit assessment for placing Kovacsin on the emergency consumption list.

Dr. Mariangela Simao, Assistant Director General (Access to Pharmaceuticals and Health Products) at the WHO told a news conference in Geneva that India Biotech is collecting data regularly and rapidly. However, he submitted the final data on October 18. Responding to a question about the delay in placing Kovacin on the emergency use list, she said China’s coronavirus vaccines have been approved despite the absence of synoform and synovac data.

When the technical advisory team met on October 26 to discuss the EUL for Kovacsin, Simao said he had sought further clarification from Bharat Biotech. WHO works closely with Bharat Biotech and interacts daily with a team of technicians to provide the required data. So far, the WHO has allowed emergency use of Pfizer-Bioentech, Astrogeneneka, Johnson & Johnson, Modernna and Sinofarm.

.

[ad_2]

Source link

Leave a Comment